Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of SGN-ALPV in advanced solid tumors
NL-OMON58634Phase 1Completed
- Sponsor
- Seagen Inc.
- Start
- May 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sgn-alpv in ovarian cancer, endometrial cancer (EC), non-small cell lung cancer (NSCLC) and 6 more (3 arms), sponsored by Seagen Inc. Primary endpoints: Adverse events and laboratory abnormalities, Dose-limiting toxicities and 1 more. Started May 2022; status: completed.
02
Drugs
sgn-alpv
03
Conditions
ovarian cancerendometrial cancer (EC)non-small cell lung cancer (NSCLC)gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON58634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58634.